Talon Therapeutics has reported a net income applicable to common stock of $29.76m, or $1.35 per share, for the third quarter ended 30 September 2012 compared to a net loss applicable to common stock of $1.71m, or $0.08 per share, for the third quarter ended 30 September 2011.
Loss from operations for third quarter of 2012 was $7.39m compared to loss from operations of $3.35m for the third quarter of 2011.
The company reported a net loss applicable to common stock of $68.69m, or $3.14 per share, for the nine months ended 30 September 2012 compared to a net loss applicable to common stock of $20.09m, or $0.94 per share, for the nine months ended 30 September 2011.
Loss of $15.48m was reported from operations for the first nine months of 2012 compared to loss of $14.78m for the first nine months of 2011.
Talon chief executive officer and board member Steven Deitcher said FDA accelerated approval of Marqibo (vinCRIStine sulfate LIPOSOME injection) is the company's most important achievement to date.
"We are in the process of evaluating a number of paths to commercialize Marqibo, including a potential strategic transaction, licensing agreement, or a Talon launch," Deitcher added.